NCT02501928 - Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2015

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions

Urinary Bladder, Neurogenic

Interventions

DRUG

Fesoterodine PR 4 mg

Fesoterodine 4 mg tablet once daily for 28 or 40 weeks

DRUG

Fesoterodine PR 8 mg

Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks

DRUG

Fesoterodine BIC 2 mg

Fesoterodine BIC 2 mg tablet once daily for 28 weeks

DRUG

Fesoterodine BIC 4 mg

Fesoterodine BIC 4 mg tablet once daily for 28 weeks

Trial Locations (7)

Aichi Children's Health and Medical Center, Ōbu

Chiba Children's Hospital, Midori-ku Chiba-shi

Fukuoka Children's Hospital, Fukuoka

Kanagawa Children's Medical Center, Yokohama

Osaka Women's and Children's Hospital, Izumi-shi

Shizuoka Children's Hospital, Aoi-ku Shizuoka-shi

Dokkyo Medical University Hospital, Shimotsuga-gun